Analystreport

CASI Pharmaceuticals, Inc. (NASDAQ: CASI) had its price target raised by analysts at HC Wainwright from $3.50 to $4.00. They now have a "buy" rating on the stock.

CASI Pharmaceuticals, Inc. - Ordinary Shares  (CASI) 
Last casi pharmaceuticals, inc. - ordinary shares earnings: 11/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: casipharmaceuticals.com/investor-relations